Aetna Wegovy Coverage · Verified April 14, 2026
Aetna Wegovy Prior Authorization: What Aetna Actually Requires, Step by Step (2026)
What we verified for this page:
Aetna Clinical Policy Bulletin 4774-C (2025 commercial PA criteria) · Aetna Policy 6410-C (cardiovascular indication) · 2026 Aetna Standard Plan Drug Guide via Formulary Navigator · 2026 Aetna Advanced Control Plan Formulary Exclusions List · CVS Caremark GLP-1 formulary update (July 2025) · Aetna Medicare drug information resources · Aetna Better Health state PA criteria PDFs (Maryland, Michigan, Florida) · NovoCare.com pricing and Wegovy Savings Card terms (January 2026).
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
If your Aetna plan includes Wegovy on its formulary, prior authorization is the standard gate to coverage — and since CVS Caremark made Wegovy its preferred GLP-1 on key formularies in July 2025, that’s a favorable position to be in. But “Aetna Wegovy prior authorization” isn’t a single yes-or-no answer, and that gap between what people expect and what the process actually requires is where approvals stall or fail entirely.
Here’s what the PA hinges on: BMI of 30 or higher (or 27+ with a qualifying health condition like hypertension, type 2 diabetes, or sleep apnea), 6 months of documented lifestyle modification (diet, exercise, structured program), and your specific plan’s benefit design — because Aetna’s own materials are clear that clinical policy bulletins do not guarantee coverage, and the member’s benefit plan governs the final answer.
The cost after approval with the Wegovy Savings Card? As low as $25/month. The timeline with complete documentation? Some members report same-day approvals; Aetna’s own guidelines say expedited exception decisions come back within 24 hours.
But here’s the catch: many Aetna benefit plans specifically exclude weight-loss medications. A commercial member, a Medicare member, and an Aetna Medicaid member can all get three different answers under the same Aetna name. That’s why we built the plan-type breakdown and documentation checklist below — so you can figure out which path applies to you before wasting time in the wrong lane.
Jump to what you need:
Which Aetna Wegovy Path Are You Actually On?
“Aetna” is not one plan — it’s a brand name that covers several different benefit structures, each with different Wegovy rules. Most pages skip this and it’s the reason so many people waste weeks in the wrong lane.
| Your Aetna Plan Type | Is Wegovy a Live Option? | PA Required? | What Matters Most | Best Next Step |
|---|---|---|---|---|
| Commercial (fully insured) — Standard Plan, Advanced Control, etc. | Yes — Preferred Brand on several key formularies | Yes | BMI, comorbidities, 6-month lifestyle documentation | Read the PA criteria and checklist below |
| Self-funded employer plan (administered by Aetna) | Depends entirely on your employer's formulary | Yes, if covered | Your employer picks the formulary. Some exclude weight loss drugs. | Call HR or the number on your card: "Is Wegovy on my plan's formulary?" |
| Aetna Medicare Advantage | Limited — generally not covered for weight-loss-only use | Yes | CV indication may be covered on certain plans; CMS Bridge program starts July 2026 | Read our Medicare Wegovy guide |
| Aetna Better Health / Medicaid | State-dependent; some states explicitly exclude Wegovy for weight loss only | Yes — often extensive step therapy | Rules vary dramatically by state. FL, IL, PA Medicaid: weight-loss-only use is an excluded benefit. | Check your state's Aetna Better Health formulary |
| Already on Wegovy, need renewal | Yes, if originally approved | Yes — new PA | Must show ≥5% baseline weight loss | Jump to Renewal Requirements section below |
Sources: Aetna Policy 4774-C (2025), 2026 Aetna Standard Plan Drug Guide, 2026 Advanced Control Plan Formulary Exclusions List, Aetna Medicare drug information page, Aetna Better Health FL/IL/PA Medicaid policy (effective April 2, 2026).
What Are Aetna’s Wegovy Prior Authorization Requirements?
For Aetna commercial plans that cover Wegovy, prior authorization criteria follow Wegovy’s FDA-approved indications. Under Aetna Policy Bulletin 4774-C, the requirements differ depending on whether Wegovy is prescribed for weight management or cardiovascular risk reduction — and whether you’re a new patient or renewing.
Adults: Wegovy for Weight Management
Under Aetna’s current non-Medicare commercial template criteria (Policy 4774-C), adults generally need all of the following:
- ✓Age 18 or older
- ✓BMI of 30 or higher (classified as obesity), or BMI of 27–29.9 with at least one weight-related comorbidity
- ✓6 months of participation in a comprehensive weight-management program that includes behavioral modification, a reduced-calorie diet, and increased physical activity — with documented follow-up
- ✓Use in combination with diet and exercise (not as a standalone treatment)
- ✓No concurrent use of other semaglutide products (Ozempic, Rybelsus) or other GLP-1 receptor agonists
Qualifying comorbidities when BMI is 27–29.9
| Condition | Common ICD-10 Codes | Notes |
|---|---|---|
| Hypertension (high blood pressure) | I10 | One of the most common qualifying conditions |
| Type 2 diabetes | E11.x | Note: if you have T2D, the separate CV pathway does NOT apply |
| Dyslipidemia (high cholesterol) | E78.x | Includes high LDL, high triglycerides |
| Obstructive sleep apnea | G47.33 | Requires documented diagnosis, ideally sleep study |
| Cardiovascular disease | I25.x, I63.x, etc. | May qualify for the separate CV pathway below |
Note: Aetna’s policy identifies qualifying comorbidity categories, but does not publish a required ICD-10 code list. The codes above are standard clinical coding for these conditions. Your provider will use the codes that match your documented diagnoses. Source: Aetna Clinical Policy Bulletin 4774-C; FDA prescribing information for Wegovy.
Adults: Wegovy for Cardiovascular Risk Reduction
Aetna maintains a separate PA pathway under Policy 6410-C for Wegovy prescribed specifically to reduce the risk of heart attack, stroke, or cardiovascular death. This matters because some plans that exclude “weight loss drugs” may still cover cardiovascular medications — same drug, different indication, different formulary category.
Requirements under the CV pathway (Policy 6410-C)
- ✓Established cardiovascular disease — documented history of MI (heart attack), stroke, or peripheral artery disease, or prior revascularization (CABG, PCI, angioplasty)
- ✓BMI of 27 or higher
- ✓No type 2 diabetes (if you have T2D, Ozempic is indicated for that population)
- ✓On guideline-directed medical therapy (GDMT) — or a documented clinical reason for not being on GDMT
- ✓Initial approval: 7 months; continuation: 12 months
Adolescents 12–17
Aetna follows the FDA-approved pediatric indication: BMI at or above the 95th percentile for age and sex, plus the same 6-month lifestyle program requirement. Continuation requires maintained or improved BMI percentile from baseline.
The caveat that makes or breaks your expectations:
Aetna’s own materials state that clinical policy bulletins help administer plan benefits but do not describe benefits and do not guarantee coverage. The member’s benefit plan governs actual coverage decisions. Decisions are made case by case, and appeals are available. Meeting every criterion on this page gives your PA the best possible chance — but it’s not a guarantee. If your specific plan has exclusions your employer chose, those override the clinical policy.
The RX Index Aetna Wegovy PA Readiness Scorecard
Walk into your doctor’s appointment knowing exactly where you stand — and exactly what documentation to bring. No other page maps Aetna’s specific criteria to a self-assessment format with preparation steps for each requirement.
| Aetna PA Requirement | What Aetna’s Reviewer Needs | What You Need to Prepare |
|---|---|---|
| BMI threshold | BMI ≥30, or BMI ≥27 with qualifying comorbidity | Recent BMI measurement (within 3–6 months) documented in medical records |
| Qualifying comorbidity (if BMI 27–29.9) | Documented diagnosis with ICD-10 code in your chart | Confirm your doctor has coded the condition — not just mentioned it in notes |
| 6-month lifestyle program | Evidence of structured program with behavioral modification, diet, and exercise | Records showing: dietitian visits, enrolled weight loss program (WW, Noom, etc.), physician-documented dietary counseling with dates |
| Step therapy (plan-specific, not universal) | Trial of ≥1 lower-cost weight loss medication (if your plan requires it) | Dates started/stopped, dose, duration, reason for stopping. Side effects and contraindications count. Common meds: Contrave, Saxenda, orlistat, phentermine, Qsymia |
| No conflicting GLP-1 use | Not currently on Ozempic, Rybelsus, Saxenda, or any other GLP-1 | Medication list confirming no concurrent semaglutide or GLP-1 RA |
| Diet and exercise plan | Provider treatment plan documenting concurrent lifestyle modifications | Ask your doctor to note in the treatment plan that Wegovy will be used alongside diet and exercise |
For renewals, add these requirements
| Renewal Requirement | What’s Needed | Preparation |
|---|---|---|
| 3+ months at stable maintenance dose | Documentation showing consistent treatment | Pharmacy fill records, provider notes |
| ≥5% baseline weight loss | Current weight vs. weight at treatment start | Weight log with dates; provider measurements at each visit |
| Continued program participation | Evidence of ongoing lifestyle modification | Recent dietitian/counseling notes or program attendance |
Is Wegovy Preferred Over Zepbound on Aetna Right Now?
On several major Aetna formularies, yes — and this matters because preferred status generally means a smoother PA pathway and lower cost-sharing.
CVS Caremark — which manages pharmacy benefits for most Aetna plans — removed Zepbound from its Standard Control, Advanced Control, and Value formularies effective July 1, 2025, while keeping Wegovy as the preferred GLP-1 for weight management:
- ✓The 2026 Aetna Advanced Control Plan lists Zepbound as a formulary exclusion, with Wegovy, Saxenda, Qsymia, and orlistat as preferred alternatives
- ✓The 2026 Aetna Standard Plan Drug Guide lists Wegovy (both oral and injectable) as a Preferred Brand with PA, Specialty Pharmacy Channel, and Quantity Limit requirements
- ✓Self-funded employer plans can differ — some employers keep Zepbound covered even though standard CVS Caremark formularies removed it
If you were considering Zepbound through Aetna, Wegovy is the easier coverage path on plans that follow CVS Caremark’s standard formularies. For self-funded plans, check with HR.
The Step-by-Step PA Process: What Actually Happens
Prior authorization is actually a straightforward documentation exercise — and understanding each step helps you avoid the delays that send people spiraling.
Verify your specific plan covers Wegovy
Call the member services number on your Aetna ID card. Ask three specific questions: (1) "Is Wegovy on my plan's formulary?" (2) "Does my plan require prior authorization for Wegovy?" (3) "Does my plan require step therapy before Wegovy?" Get the answers in writing — ask for a reference number. This 5-minute call prevents weeks of wasted effort if your plan has an exclusion.
Gather your documentation
Use the PA Readiness Scorecard above. The most common reason PAs fail is incomplete documentation, not ineligibility. Bring everything to your doctor before the visit.
Schedule a visit with your prescribing provider
At the visit, your doctor will confirm your eligibility, write the Wegovy prescription, and complete the PA form. Some offices handle PA routinely; others need guidance. Bringing the checklist helps either way.
Your doctor submits the PA to Aetna
Aetna supports electronic PA through CoverMyMeds and Surescripts (ePA). Providers can also submit by phone or fax — the specific numbers depend on your plan type and are listed on Aetna's PA resources page. Electronic submission through CoverMyMeds is generally fastest.
Wait for Aetna's decision
Aetna's Standard Plan materials state that expedited medical-exception decisions are made within 24 hours. Routine PA decisions vary — some members report approvals within hours; others experience multi-day waits, especially when documentation is incomplete. If you haven't heard back after a few business days, call the number on your member ID card to check status.
If approved
Aetna notifies your doctor and pharmacy. Fill your prescription. Present the Wegovy Savings Card at the counter — enroll free at NovoCare.com (can reduce your copay to as low as $25/month with commercial insurance, up to $100 max savings per monthly fill).
If denied
Don't stop here. Read the denial section below.
“My doctor got the PA approved within 4 hours for Aetna/Caremark.”
How Much Will Wegovy Cost With Aetna After PA Approval?
Your out-of-pocket cost depends on three things: whether your plan covers Wegovy, whether you use the Wegovy Savings Card, and whether you’ve met your deductible. Every realistic scenario in one table:
| Your Situation | Est. Monthly Cost | How It Works |
|---|---|---|
| Aetna covers Wegovy + NovoCare Savings Card | As low as $25/month | Card saves up to $100/month on your copay. Enroll free at NovoCare.com. Best-case scenario. |
| Aetna covers Wegovy, no savings card | $50–$300+/month | Depends on your plan's tier and deductible status. Specialty tier = higher. |
| Self-pay: NovoCare oral Wegovy | $149–$299/month | 1.5 mg and 4 mg = $149/month (4 mg offer through Aug 31, 2026, then $199/month). 9 mg and 25 mg maintenance = $299/month. No PA needed. |
| Self-pay: NovoCare injectable Wegovy (new patients) | $199/month for first 2 fills | Limited-time offer for 0.25 mg and 0.5 mg doses only. Available for new patients through June 30, 2026. |
| Self-pay: NovoCare injectable Wegovy (standard) | $349/month | Standard self-pay price for all injectable doses after promotional period. No PA needed. |
| Full retail, no savings | $1,349+/month | Not recommended. NovoCare offers identical FDA-approved Wegovy at far less. |
Sources: NovoCare.com Wegovy Savings Offer page and full pricing table (verified April 2026), WegovyTerms.com (savings card terms effective January 2, 2026). All promotional pricing has specific expiration dates noted — verify at NovoCare.com before relying on these numbers.
Who can’t use the savings card: Members on Medicare, Medicaid, VA, TRICARE, or any government-funded insurance — federal anti-kickback law prohibits manufacturer copay assistance for government plans.
Practical strategy: Start self-pay while PA processes simultaneously
Start on NovoCare self-pay while your PA processes. If the PA is approved, switch to insurance + savings card at your next fill and drop your cost to as low as $25/month. If it’s denied, you’re already on treatment and can pursue the appeal without a gap in medication. Oral Wegovy is available through NovoCare starting at $149/month for the 1.5 mg and 4 mg doses — no prior authorization required.
Don’t want to handle the PA paperwork yourself?
Ro’s insurance concierge checks your Aetna coverage, submits prior authorization on your behalf, follows up on pending decisions, and pursues alternative coverage pathways if you’re initially denied. If your PA is approved, stack the NovoCare Savings Card to bring your cost as low as $25/month. If not, Ro also offers Wegovy at NovoCare self-pay pricing so you can start without waiting.
Check Your Aetna Wegovy Coverage Through Ro →Ro membership from $39 first month · Affiliate link
Why People Get Denied — Even When They Seem to Qualify
Understanding why PAs fail is the fastest way to make sure yours doesn’t. These are the most common failure points, based on Aetna’s official criteria and real-world patterns.
Documentation gaps (fixable)
Missing or outdated BMI
Aetna needs a recent BMI measurement in your medical records — not a number you reported verbally. If your last documented BMI is from two years ago, the reviewer has nothing to check the box with. Fix: get a current height/weight measurement at your next visit.
Lifestyle program not formally documented
The 6-month program requirement is the most commonly underdocumented criterion. Notes saying "encouraged patient to eat better" don't qualify. What qualifies: dated records from a dietitian, formal program enrollment (WW, Noom, YMCA Weight Loss, etc.), or physician counseling notes with specific dietary and activity recommendations and follow-up visits documented.
Comorbidity diagnosed but not coded
If you have a BMI of 27–29.9, you need a qualifying comorbidity — and it needs to be in the chart with an ICD-10 code. "Patient mentions having high blood pressure" in a note is not the same as a documented, coded diagnosis. Fix: ask your doctor to confirm the diagnosis is coded correctly before the PA is submitted.
Concurrent GLP-1 not addressed
If you're already on Ozempic (semaglutide for diabetes) or any other GLP-1, the PA may be denied for concurrent use. If your doctor is transitioning you from one GLP-1 to Wegovy, the PA needs to note that the prior medication is being discontinued.
What to Do If Aetna Denies Your Wegovy Prior Authorization
| Your Denial Letter Says | What It Usually Means | Best Response | Next Step |
|---|---|---|---|
| "Medical necessity not established" | BMI documentation insufficient, or comorbidities not coded | Resubmit with updated BMI, coded comorbidities, and program documentation | Resubmit immediately |
| "Step therapy required" | Your plan requires trying a cheaper med first | Document the cheaper med trial (or clinical reason it's contraindicated), then resubmit | Varies; may need actual trial period |
| "Lifestyle modification not documented" | No evidence of 6-month weight management program | Gather program records, dietitian notes, or physician counseling documentation; resubmit | Depends on existing records |
| "Not covered" / "Excluded benefit" | Your plan's formulary excludes weight loss drugs | Request a medical exception, talk to HR, or explore the CV indication | Exception timeline varies by plan |
| "Quantity limit exceeded" | Dosing or quantity exceeds plan's allowed amount | Provider can request a quantity limit exception | Expedited decisions within 24 hours per Aetna guidelines |
| "Administrative denial" / "Wrong form" | Submission error — not a clinical judgment | Resubmit correctly via CoverMyMeds; confirm form requirements | Resubmit same day |
Your appeal roadmap
Read the denial letter carefully
It must state the specific reason. If it's vague, call Aetna at the number on your ID card and ask for the exact clinical criterion that wasn't met.
Contact your doctor's office immediately
They file the appeal — you can't submit it yourself. Share the denial reason and the specific documentation gap.
Request a peer-to-peer review
Your doctor can speak directly with Aetna's medical director. This is often the fastest path to overturning a clinical denial.
Submit with better documentation
Include a letter of medical necessity from your doctor, updated clinical records addressing the specific denial reason, and any newly available evidence.
If the internal appeal fails
You can request external review. Aetna's external review process depends on your plan type and state rules, and decisions are generally made within 30 calendar days. Follow the specific instructions in your denial letter — they'll outline your rights and timelines.
What If Your Aetna Plan Excludes Weight Loss Medications?
A plan exclusion is a fundamentally different problem than a PA denial. If your employer-sponsored plan chose a formulary that removes anti-obesity medications as a benefit category, no amount of BMI documentation will get Wegovy approved through standard PA.
If you’re facing a plan exclusion, you have four realistic paths:
Path 1
Request a medical exception
Even with an exclusion, Aetna's plan guidelines allow members and prescribers to request medical exceptions. The Aetna Standard Plan guide says expedited exception decisions are made within 24 hours. Not guaranteed to succeed — but worth attempting with strong clinical documentation.
Path 2
Advocate through HR for plan changes
Your employer chose the exclusion, and your employer can reverse it at the next renewal cycle. Novo Nordisk publishes a sample letter that healthcare providers can use to request coverage from employers. Ask your doctor to print it on their letterhead and bring it to HR.
Path 3
Use the cardiovascular indication
If you have documented heart disease, Wegovy prescribed under the CV indication may be treated differently than "anti-obesity agents" on your plan. Different coding, potentially different coverage. Whether this works depends on your specific plan design — discuss with your doctor.
Path 4
Self-pay through NovoCare
The most direct path when insurance won't work. These prices are through NovoCare Pharmacy (Novo Nordisk's direct pharmacy) and are available to anyone with a valid Wegovy prescription. No insurance needed. Ships to your door.
| Wegovy Form | Dose | Monthly Price | Notes |
|---|---|---|---|
| Oral tablet (daily) | 1.5 mg, 4 mg (starting doses) | $149/month | 4 mg offer available through August 31, 2026, then $199/month |
| Oral tablet (daily) | 9 mg, 25 mg (maintenance) | $299/month | — |
| Injectable pen (weekly) | 0.25 mg, 0.5 mg (starting — new patients) | $199/month for first 2 fills | Limited-time offer through June 30, 2026 |
| Injectable pen (weekly) | All doses (standard) | $349/month | Standard self-pay price after promotional period |
Source: NovoCare.com pricing page (verified April 2026). Government beneficiaries are not eligible for promotional pricing.
Does Aetna Medicare Cover Wegovy for Weight Loss?
Generally, no — not for weight loss alone. Aetna’s Medicare resources state that Part D covers GLP-1 medications for type 2 diabetes treatment, but Medicare plans generally do not cover GLP-1s when prescribed solely for weight loss — including Wegovy.
The exceptions are narrow:
Cardiovascular indication (plan-specific)
Some Aetna Medicare plans may cover Wegovy when prescribed for cardiovascular risk reduction in adults with established heart disease and BMI ≥27. However, we could not verify a public Aetna Medicare source that guarantees this coverage across all Aetna Medicare plans. If this pathway applies to you, ask your doctor and your Aetna Medicare plan directly.
CMS GLP-1 Bridge program (July–December 2026)
This is a separate CMS demonstration program — not an Aetna-specific benefit. Eligible Medicare Part D beneficiaries can access Wegovy or Zepbound at $50/month. PA goes through a CMS central processor, not your Aetna plan. We cover this in detail in our Medicare GLP-1 Bridge guide →
BALANCE model (January 2027+)
The longer-term successor to the Bridge, operating through your Part D plan with broader drug coverage and different cost-sharing.
If you have Aetna Medicare and want Wegovy for weight loss right now (before July 2026), your realistic options are self-pay through NovoCare ($149–$349/month depending on form and dose) or exploring whether the CV indication applies to your specific medical history and plan.
How to Keep Your Coverage: Aetna Wegovy PA Renewal
Your initial PA approval has a defined duration — Aetna’s Wegovy-specific policy specifies 7 months for initial approval and 12 months for continuation. Before it expires, your doctor needs to submit a renewal, and the renewal criteria are stricter than the initial approval.
What Aetna generally requires for renewal:
- ✓At least 3 months at a stable maintenance dose of Wegovy
- ✓At least 5% weight loss from baseline (your weight when you started treatment), achieved or maintained
- ✓Continued participation in a weight-management program (ongoing lifestyle modification documentation)
Start tracking early. Don’t wait until month 6 to check your weight loss percentage. Have your provider document your weight at every visit. If you’re approaching renewal and haven’t hit 5%, talk to your doctor about dose adjustment — the goal is to reach that threshold before the renewal submission deadline.
What if you don’t meet the 5% threshold? Your renewal will likely be denied. You can appeal with clinical justification — for example, if you’ve had meaningful improvement in comorbidities (blood pressure normalized, A1C improved, sleep apnea resolved) even without 5% weight loss, your doctor can make a medical necessity argument. But this is harder than meeting the threshold, so tracking from day one is the smartest protection.
What We Actually Verified for This Page
Most pages summarize Aetna Wegovy coverage from other summaries. We went to the source documents.
| Source Document | What We Verified | Date | Status |
|---|---|---|---|
| Aetna Policy Bulletin 4774-C (2025) | Commercial PA criteria: BMI thresholds, 6-month program, comorbidity requirements, continuation criteria (5% weight loss), approval durations (7 months initial, 12 months continuation) | April 2026 | ✅ Verified — policy visible on Aetna.com |
| Aetna Policy Bulletin 6410-C (2025) | CV indication PA criteria: established CVD, BMI ≥27, no T2D, GDMT requirement, 7-month initial approval | April 2026 | ✅ Verified |
| 2026 Aetna Standard Plan Drug Guide | Formulary status: Wegovy (oral + injectable) = Preferred Brand with PA/SPC/QL; exception and appeal procedures; expedited exception within 24 hours | April 2026 | ✅ Verified via Formulary Navigator |
| 2026 Aetna Advanced Control Plan Exclusions List | Zepbound listed as excluded; Wegovy listed as preferred alternative | April 2026 | ✅ Verified via Aetna.com |
| CVS Caremark GLP-1 formulary update | Zepbound removed from Standard Control, Advanced Control, and Value formularies July 1, 2025; Wegovy remains preferred | April 2026 | ✅ Verified via business.caremark.com |
| Aetna Medicare drug information page | Medicare generally does not cover GLP-1s for weight loss alone | April 2026 | ✅ Verified |
| Aetna Better Health FL/IL/PA Medicaid policy | Wegovy/Zepbound for weight-loss-only use is excluded benefit; CV and MASH pathways exist with separate criteria | April 2026 | ✅ Verified — effective date April 2, 2026 |
| NovoCare.com pricing + savings card | Self-pay: oral $149–$299/mo (dose-dependent), injectable $199–$349/mo (promotional terms noted); savings card: as low as $25/mo, max savings $100/mo | April 2026 | ✅ Verified — promotional expiration dates noted |
| Aetna coverage caveat | Clinical policy bulletins do not guarantee coverage; benefit plan governs | April 2026 | ✅ Verified — direct from Aetna pharmacy clinical policy page |
What we couldn’t independently verify from public documents:
Your specific plan’s step therapy requirements, whether oral and injectable Wegovy are treated identically on your plan, and whether the CV indication changes coverage on plans that exclude anti-obesity agents. These require calling the number on your Aetna member ID card.
Frequently Asked Questions: Aetna Wegovy Prior Authorization
Does Aetna require prior authorization for Wegovy?
On Aetna commercial plans that include Wegovy on their formulary, prior authorization is typically required. Your doctor submits documentation proving you meet Aetna's medical necessity criteria — including BMI thresholds, qualifying health conditions, and evidence of prior lifestyle modification efforts. Providers can submit electronically through CoverMyMeds or Surescripts, or by phone, fax, or mail.
What BMI do you need for Aetna to approve Wegovy?
Under Aetna's commercial PA template criteria (Policy 4774-C), adults need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Adolescents ages 12–17 need a BMI at or above the 95th percentile for their age and sex.
How long does Aetna prior authorization take for Wegovy?
There is no universal turnaround guarantee. Aetna's Standard Plan materials state that expedited medical-exception decisions are made within 24 hours. Public experience reports range from same-day approvals to multi-week delays, with the biggest variable being how quickly and completely the prescriber's office submits documentation. Incomplete submissions are the most common cause of extended timelines.
What do I do if Aetna denies my Wegovy prior authorization?
First, identify whether the denial is for missing documentation, unmet criteria, or a true plan exclusion — these require different responses. For documentation issues, have your doctor resubmit with the missing evidence. For criteria issues, request a peer-to-peer review with Aetna's medical director. For plan exclusions, request a medical exception or explore self-pay options through NovoCare Pharmacy — oral Wegovy starts at $149/month for 1.5 mg and 4 mg doses, injectable at $349/month ($199/month for new patients through June 30, 2026).
Does Aetna Medicare cover Wegovy for weight loss?
Generally, no. Aetna's Medicare resources state that Medicare Part D does not cover GLP-1 medications prescribed solely for weight loss. Wegovy may be covered on certain Aetna Medicare plans when prescribed for cardiovascular risk reduction in adults with established heart disease and BMI of 27 or higher — but this is plan-specific and not guaranteed. A CMS demonstration program (the Medicare GLP-1 Bridge) launches July 1, 2026 offering eligible beneficiaries Wegovy or Zepbound at $50/month.
Is Wegovy preferred over Zepbound on Aetna?
On several major Aetna plan formularies — including the Aetna Standard Plan and Advanced Control Plan — Wegovy is listed as a Preferred Brand while Zepbound is excluded. This reflects CVS Caremark's July 2025 decision to remove Zepbound from its Standard Control, Advanced Control, and Value formularies while keeping Wegovy preferred. However, some Aetna plan configurations may differ. Always verify your specific plan's formulary.
Can Aetna approve Wegovy for heart disease?
Aetna has a separate commercial PA pathway under Policy 6410-C for Wegovy prescribed for cardiovascular risk reduction. This applies to adults with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), BMI of 27 or higher, who do not have type 2 diabetes, and are on guideline-directed medical therapy (GDMT). Initial approval under this pathway is 7 months.
What if my Aetna plan excludes weight loss medications entirely?
A plan exclusion is different from a PA denial. If your employer or plan specifically excludes anti-obesity medications, your options include: requesting a medical exception through your plan, asking HR to reconsider at the next plan renewal, using the cardiovascular indication if you have documented heart disease, or accessing Wegovy through self-pay — oral Wegovy starts at $149/month for 1.5 mg and 4 mg doses, and injectable at $349/month ($199/month for new patients through June 30, 2026), through NovoCare Pharmacy with no PA required.
Does the Wegovy Savings Card work with Aetna?
Yes. If your Aetna commercial plan covers Wegovy, the NovoCare Savings Card lets you pay as little as $25 per month (maximum savings of $100 per one-month supply). The card is free and available at NovoCare.com. It is not available to members on Medicare, Medicaid, or other government insurance programs.
What if my doctor's office won't handle the prior authorization?
Bring the documentation checklist from this page to your appointment so the office has a clear roadmap. Providers can submit through CoverMyMeds (the primary electronic system Aetna supports), Surescripts, or by phone/fax using the numbers on Aetna's PA resources page. Alternatively, telehealth providers like Ro include insurance concierge services — their team handles PA submissions, follow-ups, and appeals as part of the membership.
By The RX Index Editorial Team · Last verified: April 14, 2026. Created from official Aetna, CVS Caremark, and FDA sources. Reddit and forum quotes are used only to illustrate reader friction and voice — never as evidence for medical, regulatory, or coverage claims. We do not add a “medically reviewed by” claim because no physician reviewed this editorial content.
Related guides and resources
- How to appeal a Wegovy denial: 7 steps (2026)
- Does insurance cover Wegovy for weight loss? Complete guide by plan type
- Does Medicare cover Wegovy for weight loss?
- Medicare GLP-1 Bridge Program: $50/month starting July 2026
- Best telehealth providers for Wegovy in 2026
- GLP-1 providers that accept Aetna: full 2026 comparison
Still not sure which GLP-1 path is right for you?
Our free 60-second quiz considers your insurance, budget, and preferences to recommend the right verified provider.
Take Our Free GLP-1 Matching Quiz →Affiliate disclosure: Some links on this page are affiliate links. We may earn a commission if you start a program through our links. Our coverage information is based on verified policy documents and public formulary data — not commission rates.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, changing, or stopping any medication. Coverage information reflects publicly available Aetna policy documents and may not reflect your specific plan’s benefits.
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We re-verify pricing and policies monthly.